Arrangement and method for producing a transjugular implanted intra-arterial port system for the therapy of liver malignancies
The transjugular implanted intra-arterial port system addresses the limitations of current therapies by providing a minimally invasive, secure, and prolonged access to the hepatic artery for drug delivery, enhancing treatment efficacy for liver malignancies.
Patent Information
- Application Number
- PCT/EP2025/063246
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Existing treatments for liver malignancies, particularly those that are intermediately or hypovascularized, face challenges due to the limitations of current intra-arterial therapies, including the need for frequent catheterization, high risk of thrombosis, and short lifespan of surgically placed ports, making long-term or repetitive chemotherapy cycles difficult.
A transjugular implanted intra-arterial port system is developed, comprising a measuring microcatheter, steerable puncture needle, guide wire, kink-resistant port microcatheter, stent guidewire, and antithrombotic stent, allowing for minimally invasive implantation and secure connection to a port chamber, enabling prolonged access to the hepatic artery for drug delivery.
The system allows for prolonged, minimally invasive, and secure delivery of therapeutic agents directly to the hepatic artery, reducing thrombotic risk and patient burden, suitable for extended chemotherapy cycles without the need for repeated surgical interventions.
Smart Images

Figure EP2025063246_19112026_PF_FP_ABST
Abstract
Description
[0001] 25046PW001
[0002] Prof. Dr. med. Attila Kovacs
[0003] 53639 Königswinter
[0004] Arrangement and procedure for the fabrication of a transjugular implanted intra-arterial port system for the treatment of liver malignancies
[0005] Description:
[0006] The invention relates to an arrangement and a method for manufacturing a transjugular implanted intra-arterial port system for the treatment of liver malignancies.
[0007] Primary (primary liver tumors) and secondary (metastases) liver malignancies are among the most common oncological diseases. Approximately 80% of patients with solid tumors develop liver metastases during the course of their disease. These metastases severely impair liver reserve and, in most cases, reduce life expectancy and quality of life. Therapeutic options of any kind are also significantly limited when liver reserve is compromised. At most, 20% of liver metastases are surgically resectable. Only 20% of liver malignancies (primary and secondary) are hypervascularized, meaning they have a higher blood supply than healthy liver tissue and are therefore well-suited for intra-arterial locoregional therapies (IALT), such as TACE (transarterial chemoembolization) and SIRT (selective internal radiation therapy). The advantage of IALT is that it achieves greater therapeutic efficacy in the liver with significantly fewer systemic side effects.The remaining 80% of liver malignancies are intermediately or hypovascularized, meaning they have the same or worse blood flow than healthy liver tissue and pose a challenge not only for IALT.
[0008] These advantages are not only significant but are also associated with a poorer response to therapy. Good results can be achieved with intra-arterial chemoperfusion (IACP) in hypovascularized lesions. In this procedure, tumor-affected areas in the liver are targeted locoregionally and slowly saturated with a drug or drug combination. Unlike TACE, the therapeutic agent is not bound to particles. The best results with IACP are achieved when treatments are administered at short intervals (daily or every two days).This leads to a particular dilemma and severely limits the technical feasibility, on the one hand because the microcatheters required for administering the therapeutic agent cannot be left freely floating in the arterial system for days due to a significant risk of thrombosis, and on the other hand, daily / bi-day catheterization cannot be expected of the patient due to the risks of puncture, the risk of thrombosis associated with prolonged indwelling, repetitive administration of contrast agents, radiation exposure, etc.
[0009] One possible alternative is a surgically placed intra-arterial port, as described in Mahnken AH, Pereira PL, Baere Td, Interventional Oncologic Approaches to Liver
[0010] Metastases, Radiology and Deschamps F., Rao P., Teriitehau C., Hakime A., Malka D., Böige V., Ducreux M., Elias D., Goere D., de Baere T. Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: Feasibility and predictive factors of long-term functionality, J. Vase. Interv. Radiol. 2010;21:1681-1688. A disadvantage is the burdensome and immunosuppressive surgical procedure. Even more limiting, however, is the short lifespan of these port systems, which are usually only functional for 4 to 5 chemotherapy cycles and then must be surgically removed. This means that this technique is unsuitable for longer or repetitive chemotherapy cycles, as desired by hematologists / oncologists.
[0011] The object of the invention is therefore to propose an arrangement and a method with which a minimally invasive implantable system is created which can remain in place for a longer period of time with low patient burden and can also be used for longer and possibly repetitive therapy cycles and overcomes the disadvantages of the previous state of the art.
[0012] To solve the stated problem, an arrangement for producing a transjugular implanted intra-arterial port system for the therapy of liver malignancies is proposed according to the invention, in accordance with the features of claim 1.
[0013] A method for manufacturing a transjugular implanted intra-arterial port system for the treatment of liver malignancies is the subject of claim 7.
[0014] Advantageous embodiments and further developments of the invention are the subject of the dependent claims.
[0015] The arrangement according to the invention comprises
[0016] - a measuring microcatheter with a radiopaque design at least of the distal end region;
[0017] - a puncture set with a steerable puncture needle that can be advanced in a catheter and a steerable microcatheter that can be advanced through the puncture needle;
[0018] - a guide wire that can be advanced through the steerable microcatheter;
[0019] - a kink-resistant port microcatheter that can be guided over the guide wire and has a radiopaque design at least of the distal end region;
[0020] - a stent guidewire that can be inserted into the measuring microcatheter and
[0021] - an antithrombotic coated expandable stent that can be guided over the stent guide wire, as well as
[0022] - an implantable port chamber
[0023] wherein the lengths of the measuring microcatheter, the puncture set, the guide wire, the port microcatheter and the stent guide wire are dimensioned such that, when the measuring microcatheter is positioned starting from the right femoral aorta, the distal end extends into the side branch of the right hepatic artery covered by liver parenchyma;
[0024] - when positioning the puncture set starting from the right internal jugular vein, the puncture needle extends into the right hepatic vein adjacent to the measuring microcatheter located in the right hepatic artery, and the adjacent right hepatic artery can be punctured using the puncture needle, so that the steerable microcatheter can be inserted into the hepatic artery in the direction of the porta hepatis;
[0025] - the guide wire can be inserted through the steerable microcatheter via the hepatic artery into the abdominal aorta;
[0026] - can be inserted into the hepatic artery via the guide wire of the port microcatheter
[0027] - the stent guide wire can be inserted through the measuring microcatheter into the hepatic artery.
[0028] Furthermore, the port microcatheter according to the invention is provided at its proximal end, which is away from the hepatic artery, with a conically widened connection section for connection to the port chamber.
[0029] According to one aspect of the invention, the port chamber has a connection nozzle with a sleeve formed radially around the connection nozzle, and the port microcatheter has a radially projecting circumferential locking ring on its connection section, which can be positively locked to the sleeve when the connection section is connected to the connection nozzle, so that the port microcatheter can be securely connected to the connection nozzle of the port chamber in the manner of a plug connection, which offers a high degree of security against unwanted loosening of this connection.
[0030] According to a further aspect of the invention, a locking device is also provided for securing the connection section to the connection nozzle. Such a locking device can, according to the invention, be formed by a tubular cuff that is slidably guided along the outer circumference of the port microcatheter and can be positioned over the connection section attached to the connection nozzle.
[0031] A further aspect of the invention provides that the distal end of the port microcatheter is externally tapered to form a region that remains free when the distal end of the port microcatheter is secured in the hepatic artery by means of an expandable stent, so that it is not occluded by the stent during the resulting jailing. The tapered distal end of the port microcatheter is also preferably designed to be compression-resistant.
[0032] A further embodiment of the invention provides that the distal end of the port microcatheter is bent back or backward by at least 90°, preferably up to 180°, relative to its straight course over a length of preferably approximately 4-10 mm and is provided with a radiopaque marker. This ensures that, after removal of the guidewire used for insertion, the distal end of the port microcatheter, with the distal exit opening of the continuous lumen typically located there, aligns itself in such a relaxed position that the distal end points in the direction of blood flow within the hepatic artery. This counteracts thrombotic occlusion.
[0033] The arrangement according to the invention, thus designed, makes it possible to create a transjugular implanted intra-arterial access via a port system, in order to effectively treat liver malignancies in particular.
[0034] For this purpose, the invention proposes the sequence of steps shown below for applying the arrangement according to the invention: - Insertion of a measuring microcatheter into the right femoral aorta and into the side branch of the right hepatic artery covered by liver parenchyma;
[0035] - Performing a three-dimensional imaging of the liver and positioning the tip of the measuring microcatheter, located in the right hepatic artery, immediately adjacent to the right hepatic vein;
[0036] - Insertion of a puncture set with a steerable puncture needle into the right internal jugular vein and into the right hepatic vein adjacent to the measuring microcatheter located in the right hepatic artery;
[0037] - Puncture and guidance of the puncture needle from the right internal jugular vein into the right hepatic artery and insertion of a steerable microcatheter through the puncture needle towards the porta hepatis;
[0038] - Insertion of a guide wire via the microcatheter into the hepatic artery and into the abdominal aorta;
[0039] - Removal of the microcatheter while leaving the guidewire in place and subsequent insertion of a port microcatheter over the guidewire into the hepatic artery parallel to the measuring microcatheter to create an arterial port access;
[0040] - Insertion of a stent guidewire into the measuring microcatheter and subsequent removal of the measuring microcatheter from the arterial vascular system, as well as insertion of an expandable stent over the stent guidewire and expansion of the same while fixing the distal end of the port microcatheter to the inner wall of the hepatic artery;
[0041] - Removal of the puncture set and guide wire as well as the stent guide wire and connection of the proximal end of the port microcatheter to a port chamber.
[0042] Thus, according to the invention, it is possible to use a port chamber known and advantageous from the venous administration of therapeutically active substances with the aid of the arrangement according to the invention, but to extend the port microcatheter leading from the port chamber and serving to guide and administer the therapeutically active substance to a target area in one of the hepatic arteries, wherein the change or transition from the entry-side access used via the venous blood circulation to the exit-side exit used in the arterial blood circulation takes place in a reliably marked area covered by liver parenchyma by means of a puncture, so that the risk of unwanted bleeding is minimized.
[0043] According to a proposal of the invention, the connection of the proximal end of the port microcatheter to the port chamber can be carried out by means of a locking plug connection with subsequent securing of the connection by actuating a locking device.
[0044] Furthermore, it may be provided that the expandable stent is expanded at a distance of 3 to 8 mm from the distal end of the port microcatheter.
[0045] In an advantageous embodiment of the invention, it is provided that the distal end of the port microcatheter is bent back by up to 180° relative to its straight course over a length range of 4 to 10 mm and is provided with a radiopaque marker, and after removal of the guide wire, the distal end of the port microcatheter is enabled to bend back by up to 180° relative to the course of the port microcatheter in the direction of the arterial blood flow in the hepatic artery in order to point in the direction of the blood flow and to counteract thrombotic occlusion.
[0046] An advantageous implantation technique for the arrangement according to the invention proceeds as follows:
[0047] Under analgosedation / general anesthesia and after local anesthesia, the right internal jugular vein is punctured under ultrasound guidance and a long sheath is inserted, as is clinical standard, for example, in procedures to create a transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of hypertension in the portal vein leading to the liver.
[0048] Following local anesthesia, the right femoral artery is punctured, a short sheath is inserted, and the measuring microcatheter of the inventive arrangement is positioned coaxially in a side branch of the right hepatic artery that is adequately covered by liver parenchyma. This measuring microcatheter serves as a clearly visible navigation aid in the subsequent implantation steps and for marking the target area for the implantation of the port microcatheter.
[0049] A 3D scan of the liver is performed, for example using cone-beam CT, to determine the optimal position for the subsequent puncture from the hepatic vein into the hepatic artery. The indwelling measuring microcatheter serves to precisely define the landing zone for the transhepatic puncture from the hepatic vein.
[0050] The puncture device is then used to target the landing zone in the hepatic artery via the right hepatic vein, and starting from the hepatic vein, the hepatic artery in the target area is punctured to create the desired transition between venous and arterial blood circulation.
[0051] After successful puncture of the artery, a steerable microcatheter is inserted via the puncture set, thereby overcoming the acute angle towards the porta hepatis.
[0052] A long, stable microwire is then inserted into the central segment of the hepatic artery via the steerable microcatheter. Preferably, the tip of the microwire is positioned generously above the celiac trunk into the abdominal aorta to ensure the necessary stability. The steerable microcatheter is then removed, and the port microcatheter, preferably with a gauge of 2.0–2.4 F, is inserted using the Seldinger technique over the microwire. The tip of the port microcatheter is aligned with the indwelling measuring microcatheter to ensure optimal coverage of the entire liver with the therapeutic fluid delivered through the port microcatheter's continuous lumen, thus enabling local chemotherapy of the liver and any metastases present there.
[0053] Depending on the anatomy and proximity of the origin of the gastroduodenal artery to the tip of the port microcatheter, the gastroduodenal artery may need to be closed off, analogous to SIRT, which can be achieved, for example, using coils or an Amplatzer device.
[0054] The measuring microcatheter is then removed over an inserted or embedded microwire, which subsequently serves as a stent guidewire. The expandable stent is then advanced over this guidewire, and the port microcatheter with the stent, which is preferably coated with an antithrombotic agent, is fixed to the vessel wall – a procedure also known as "jailing." During jailing, it is important to ensure that approximately 5 mm of the distal end of the port microcatheter is not covered by the stent but protrudes beyond it.
[0055] The jugular puncture set can then be completely removed.
[0056] The proximal end of the port microcatheter can be tunneled into the right subclavian fossa. Sufficient loop must be ensured so that no tension is exerted on the intrahepatic portion of the port microcatheter, regardless of the patient's head and arm movements.
[0057] The proximal (port chamber-near) end of the port microcatheter is now located in
[0058] the right subclavian fossa and is ready for connection to the port chamber. After connecting the port microcatheter, the opening can be closed with a skin suture and sterile adhesive dressing.
[0059] Further embodiments and details of the invention are explained below with reference to exemplary embodiments in the drawing. The drawing shows:
[0060] Figure 1: a schematic view of a patient to be treated;
[0061] Figure 2: Simplified enlarged view of the patient's liver as shown in Figure 1;
[0062] Figure 3: a further enlarged view of a detail of Figure 2;
[0063] Figure 4: Connection of the proximal end of the port microcatheter to the port chamber;
[0064] Figure 5: a section through the connection area of the proximal end of the port microcatheter according to Figure 1 in the unconnected state;
[0065] Figure 6: section through the connection area of the proximal end of the port microcatheter according to Figure 1 in the connected state;
[0066] The schematic representation of Figure 1 shows a patient P, whose liver 8, surrounded by liver parenchyma 80, is depicted.
[0067] For the treatment of liver malignancies found on liver 8, an arrangement consisting of the components described below is used to periodically or continuously administer a drug for local chemotherapy into a branch of the hepatic artery (A. hepatica) over a predetermined period. For this purpose, different access routes are opened in the patient P2, which are described below. First, under analgesia and sedation or general anesthesia, the right internal jugular vein is punctured under ultrasound guidance, and a long sheath is inserted to introduce a puncture set 4. The puncture set 4 is dimensioned such that its distal end, as shown, can be advanced via the venous blood vessel system into the hepatic vein 7 of the patient's liver 8.
[0068] Furthermore, prior to or following local anesthesia, the right femoral aorta is punctured, preferably in the groin region, and a short sheath is inserted. A measuring microcatheter 3 is then introduced via this access point using a coaxial technique. Its dimensions allow the distal end 30 to be positioned in a side branch of the right hepatic artery 6 covered by liver parenchyma 80, as shown in Figure 2.
[0069] The liver 8 can then be shown in a 3D image, e.g. in a cone CT scan, as indicated in Figure 2, where in Figure 2 the direction of arterial blood flow is denoted by A and the direction of venous blood flow by V.
[0070] The radiopaque distal end 30 of the measuring microcatheter 3 then allows the target region Z2 for optimal puncture of the hepatic artery 6 from the hepatic vein 7 to be marked using the puncture set 4. This target region Z2 is adjacent to a crossing or a parallel course of the hepatic vein 7. Similarly, the target region Z1 for the puncture set 4 is also defined; this is located in the immediate vicinity of the target region Z2 of the hepatic artery 6.
[0071] Using the inserted measuring microcatheter, the landing zone for a transhepatic puncture of the hepatic artery 6 from the hepatic vein 7 can be precisely marked at its distal end 60 and subsequently targeted within the hepatic vein 7 using the puncture set 4. The hepatic artery 6 is then punctured in the target region Z2 using the puncture needle of the puncture set 4, and a steerable microcatheter is inserted into the hepatic artery 6 through the puncture set 4, thus overcoming the acute angle towards the porta hepatis.
[0072] Next, a suitably long and stable micro-guidewire can be placed into the central section of the hepatic artery 6 via the steerable microcatheter, with the tip of the guidewire being generously placed and positioned over the celiac trunk into the abdominal aorta to ensure sufficient stability.
[0073] The steerable microcatheter can now be removed, and a port microcatheter 1 of suitable length and with a gauge of approximately 2.0 to 2.4 F is inserted using the Seldinger technique and advanced along the guidewire into the hepatic artery 6. As shown in Figure 3, the port microcatheter exits the hepatic vein 7 through the puncture port 70 at puncture site Z1, Z2 and enters the hepatic artery 6 through the puncture port 60. The distal end 14 of the port microcatheter is aligned using the still-in-place measuring microcatheter 3 to ensure optimal coverage of the entire liver 8 with the chemotherapy drug delivered via the port microcatheter 1.
[0074] Depending on the anatomy and proximity of the origin of the gastroduodenal artery to the distal end 14 of the port microcatheter 1, the gastroduodenal artery may need to be closed off as in SIRT, which can be done, for example, using a coil or an Amplatzer device.
[0075] Next, the measuring microcatheter 3 can be removed over an indwelling or inserted stent guidewire 5. An antithrombotic-coated expandable stent 50 is then introduced over the stent guidewire 5 and deployed adjacent to the distal end 14 of the port microcatheter 1 in the hepatic artery 6. In this way, the port microcatheter 1 is secured, or jailed, in its target position within the hepatic artery 6 by means of the expanded stent 50. During jailing, care must be taken to ensure that at least approximately 10 mm of the distal end 14 of the port microcatheter 1 is not covered by the stent 5, but extends beyond it. Furthermore, the distal end not secured by the stent may be slightly tapered towards its free end.
[0076] Once the stent guidewire has also been removed, a pre-introduced deformation of the distal end 14 of the measuring microcatheter 1 over a length 15 of approximately 4 to 10 mm causes the free end to bend by approximately 180° relative to the straight orientation of the port microcatheter, so that the distal exit port 140 of the port microcatheter 1 points in the direction of the arterial blood flow A within the hepatic artery 6. This minimizes the risk of thrombosis.
[0077] Now the puncture set 4 can also be removed, leaving only the port microcatheter 1 in patient P. The proximal segment can be tunneled into the right subclavian fossa, ensuring a sufficiently large loop so that no traction is exerted on the intrahepatic segment of the port microcatheter 1, regardless of patient P's head and arm movements.
[0078] The proximal end 10 of the port microcatheter 1 is now located in the right subclavian fossa and is ready for connection to a provided port chamber 2.
[0079] Figure 4 shows the port chamber 2 with the membrane 20, which can be punctured externally, and a radially projecting connection nozzle 21. Near its free end, the essentially cylindrical connection nozzle 21 has a radially circumferential thickening or lip 22.
[0080] The depicted proximal end 10 of the port microcatheter 1 is conically widened towards its end to facilitate its attachment to the connector 21, with the outer diameter increasing towards the proximal end 10. On its inner surface, the proximal end 10 is formed with an inwardly projecting circumferential sleeve 11 adapted to the lip 22. As shown in the comparative illustrations in Figures 5 and 6, this sleeve engages with the connector 21 when placed onto it, thus providing a positive fit and securing the proximal end 10 in the assembly mounted and connected to the connector 21. This allows a therapeutically effective drug for chemotherapy of the liver to be injected into the port microcatheter 1 via the membrane 20 and the port chamber 2, and through its continuous lumen to the distal end of the same, in order to administer the drug directly into the hepatic artery.
[0081] A further improvement in the connection locking mechanism designed in this way between the port microcatheter 1 and the connection nozzle 21 of the port chamber 2 is achieved by a concentrically designed cuff 12 which is slidably guided on the port microcatheter 1 and which, after the proximal end 10 of the port microcatheter 1 has been attached and locked onto the connection nozzle 21 according to Figure 6, is pushed over the area of the mutually loaded sleeve 11 and lip 22 and reliably prevents the proximal end 10 of the port microcatheter 1 from detaching from the connection nozzle 21.
[0082] Such double protection through the latched connection between sleeve 11 and lip 22 and the cuff 12 pushed over it allows higher injection pressures to be used.
[0083] The arrangement and procedure described above make it possible to administer a drug directly and precisely into the hepatic artery at a high frequency over a desired period, starting from a port chamber that has proven effective in chemotherapy and is gentle on the patient. This significantly increases efficacy, particularly in the treatment of intermediately or hypovascularized liver malignancies, without an increased risk of thrombosis or excessive burden on the patient from surgical interventions, and is achieved minimally invasively. Reference list:
[0084] 1: Port microcatheter 2: Port chamber
[0085] 3: Measuring microcatheter 4: Puncture set 5: Stent guidewire 6: Right hepatic artery 7: Right hepatic vein 8: Liver
[0086] 10: proximal end 11: sleeve
[0087] 12: Cuff
[0088] 14: distal end
[0089] 15: Length range 20: Membrane
[0090] 21: Connection stub 22: Lip
[0091] 30: distal end
[0092] 50: Stent
[0093] 60: Puncture opening 70: Puncture opening 80: Liver parenchyma 140: Exit opening
[0094] A: arterial blood flow P: patient
[0095] V: venous blood flow Z1: target position
[0096] Z2: Target position
Claims
Patent claims:
1. Order for the fabrication of a transjugular implanted intra-arterial port system for the treatment of liver malignancies, comprising - a measuring microcatheter (3) with a radiopaque design at least of the distal end region (30); - a puncture set (4) comprising a steerable puncture needle which can be advanced in a catheter and a steerable microcatheter which can be advanced through the puncture needle; - a guide wire that can be advanced through the steerable microcatheter; - a kink-resistant port microcatheter (1) that can be guided over the guide wire and has a radiopaque design at least of the distal end region (14); - a stent guidewire (5) that can be inserted into the measuring microcatheter (3) and - an antithrombotic coated expandable stent (50) that can be guided over the stent guide wire (5), - an implantable port chamber (2) wherein the lengths of the measuring microcatheter (3), the puncture set (4), the guide wire, the port microcatheter (1) and the stent guide wire (5) are dimensioned such that - when positioning the measuring microcatheter (3) starting from the right femoral aorta, the distal end (30) extends into the side branch of the right hepatic artery (6) covered by liver parenchyma (80); - when positioning the puncture set (4) starting from the right internal jugular vein, the puncture needle extends into the right hepatic vein (7) adjacent to the measuring microcatheter (3) lying in the right hepatic artery (6), and the adjacent right hepatic artery (6) can be punctured by means of the puncture needle, so that the steerable microcatheter can be inserted into the hepatic artery (6) in the direction of the porta hepatis; - the guidewire can be inserted through the steerable microcatheter via the hepatic artery (6) into the abdominal aorta; - the port microcatheter (1) can be inserted via the guidewire into the hepatic artery (6). - the stent guide wire (5) can be inserted through the measuring microcatheter (3) into the hepatic artery (6), and wherein the port microcatheter (1) is provided at its proximal end (10) facing away from the hepatic artery with a conically widened connection section for connection to the port chamber (2).
2. Arrangement according to claim 1, characterized in that the port chamber (2) has a connection nozzle (21) with a sleeve (22) formed radially around the connection nozzle (21) and the port microcatheter (1) has a radially projecting circumferential locking ring (11) on its connection section, which can be positively locked to the sleeve (22) when the connection section is connected to the connection nozzle (21).
3. Arrangement according to one of claims 1 or 2, characterized in that a securing device for securing the connection section on the connection nozzle (21) is provided.
4. Arrangement according to claim 3, characterized in that the securing device is formed by a tubular cuff (12) which is slidably guided along the port microcatheter (1) on its outer circumference and can be positioned via the connecting section connected to the connecting nozzle (21).
5. Arrangement according to any one of claims 1 to 4, characterized in that the distal end (14) of the port microcatheter (1) is conically tapered on the outside.
6. Arrangement according to any one of claims 1 to 5, characterized in that the distal end (14) of the port microcatheter (1) is bent back by 180° relative to its straight course over a length range of 4 to 10 mm and is provided with a radiopaque marker.
7. Method for manufacturing a transjugular implanted intra-arterial port system for the treatment of liver malignancies, comprising: - Insertion of a measuring microcatheter (3) into the right femoral aorta and into the side branch of the right hepatic artery (6) covered by liver parenchyma (80); - Performing a three-dimensional imaging of the liver (8) and positioning the tip of the measuring microcatheter (3) located in the right hepatic artery (6) immediately adjacent to the right hepatic vein (7); - Insertion of a puncture set (4) with a steerable puncture needle into the right internal jugular vein and into the right hepatic vein (7) adjacent to the measuring microcatheter (3) located in the right hepatic artery (6); - Puncture and guidance of the puncture needle from the hepatic vein (7) into the right hepatic artery (6) and insertion of a steerable microcatheter via the puncture needle towards the porta hepatis; - Insertion of a guide wire via the microcatheter into the hepatic artery (6) and into the abdominal aorta; - Removal of the microcatheter while leaving the guidewire in place and subsequent insertion of a port microcatheter (1) over the guidewire into the hepatic artery (6) parallel to the measuring microcatheter (3) to create an arterial port access; - Insertion of a stent guidewire (5) into the measuring microcatheter (3) and subsequent removal of the measuring microcatheter (3) from the arterial vascular system as well as insertion of an expandable stent (50) over the stent guidewire (5) and expansion of the same while fixing the distal end region (14) of the port microcatheter (1) to the inner wall of the hepatic artery (6); - Removal of the puncture set (4) and guide wire and stent guide wire (5) and connection of the proximal end (10) of the port microcatheter (1) to a port chamber (2).
8. Method according to claim 7, characterized in that the connection of the proximal end (10) of the port microcatheter (1) to the port chamber (2) is carried out by means of a locking plug connection with subsequent securing of the connection by actuating a locking device.
9. Method according to claim 7 or 8, characterized in that the expandable stent (5) is expanded at a distance of at least 5 mm from the distal end (14) of the port microcatheter (1).
10. Method according to one of claims 7 to 9, characterized in that the distal end (14) of the port microcatheter (1) is bent back by 180° relative to its straight course over a length range of 4 to 10 mm and is provided with a radiopaque marker and, after removal of the guide wire, the distal end (14) of the port microcatheter (1) is enabled to bend back by 180° relative to the course of the port microcatheter (1) in the direction of the arterial blood flow in the hepatic artery (6).
